posted on 2017-02-21, 00:00authored byRosa Crespo, Eva Villar-Alvarez, Pablo Taboada, Fernando A. Rocha, Ana M. Damas, Pedro M. Martins
The
study of drug candidates for the treatment of amyloidosis and
neurodegenerative diseases frequently involves in vitro measurements
of amyloid fibril formation. Macromolecular crowding and off-pathway
aggregation (OPA) are, by different reasons, two important phenomena
affecting the scalability of amyloid inhibitors and their successful
application in vivo. On the one hand, the cellular milieu is crowded
with macromolecules that drastically increase the effective (thermodynamic)
concentration of the amyloidogenic protein. On the other hand, off-pathway
aggregates, rather than amyloid fibrils, are increasingly appointed
as causative agents of toxicity. The present contribution reveals
that insoluble off-pathway aggregates of hen egg-white lysozyme (HEWL)
are a peculiar type of crowding agents that, unlike classical macromolecular
crowders, decrease the thermodynamic concentration of protein. Illustrating
this effect, OPA is shown to resume after lowering the fraction of
insoluble aggregates at a constant soluble HEWL concentration. Protein
depletion and thioflavin-T fluorescence progress curves indicate that
OPA rebirth is not accompanied by additional amyloid fibril formation.
The crystallization-like model extended to account for OPA and time-dependent
activity coefficients is able to fit multiple kinetic results using
a single set of three parameters describing amyloid nucleation, autocatalytic
growth, and off-pathway nucleation. The list of fitted results notably
includes the cases of aggregation rebirth and all types of progress
curves measured for different HEWL concentrations. The quantitative
challenges posed by macromolecular crowding and OPA find here a unified
response with broader implications for the development of on- and
off-pathway inhibitors.